BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34431316)

  • 1. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.
    Comito F; Marchese PV; Ricci AD; Tober N; Peterle C; Sperandi F; Melotti B
    Future Oncol; 2021 Nov; 17(33):4583-4606. PubMed ID: 34431316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.
    Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM
    Ann Oncol; 2019 Aug; 30(8):1370-1380. PubMed ID: 31150059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic disease from uveal melanoma: treatment options and future prospects.
    Carvajal RD; Schwartz GK; Tezel T; Marr B; Francis JH; Nathan PD
    Br J Ophthalmol; 2017 Jan; 101(1):38-44. PubMed ID: 27574175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
    Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
    Niederkorn A; Wackernagel W; Artl M; Schwantzer G; Aigner B; Richtig E
    Acta Ophthalmol; 2014 Dec; 92(8):e696-7. PubMed ID: 24774993
    [No Abstract]   [Full Text] [Related]  

  • 7. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases.
    Carr MJ; Sun J; Cohen JB; Liu J; Serdiuk AA; Stewart SR; Doobay N; Duclos A; Seal DA; Choi J; Zager JS
    Cancer Control; 2020; 27(1):1073274820983019. PubMed ID: 33372814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?
    Sacco JJ; Kalirai H; Kenyani J; Figueiredo CR; Coulson JM; Coupland SE
    Future Oncol; 2018 Jun; 14(14):1335-1338. PubMed ID: 29741103
    [No Abstract]   [Full Text] [Related]  

  • 9. Uveal melanoma.
    Spagnolo F; Caltabiano G; Queirolo P
    Cancer Treat Rev; 2012 Aug; 38(5):549-53. PubMed ID: 22270078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.
    Bedikian AY; Legha SS; Mavligit G; Carrasco CH; Khorana S; Plager C; Papadopoulos N; Benjamin RS
    Cancer; 1995 Nov; 76(9):1665-70. PubMed ID: 8635073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of metastatic uveal melanoma: review and recommendations.
    Albert DM; Niffenegger AS; Willson JK
    Surv Ophthalmol; 1992; 36(6):429-38. PubMed ID: 1589858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term progression-free survival in metastatic uveal melanoma after chemoimmunotherapy and consolidation thermoablation.
    Al-Jamal RT; Eskelin S; Pyrhönen S; Kivelä T
    Acta Oncol; 2009; 48(3):476-9. PubMed ID: 19031163
    [No Abstract]   [Full Text] [Related]  

  • 13. Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives.
    Buder K; Gesierich A; Gelbrich G; Goebeler M
    Cancer Med; 2013 Oct; 2(5):674-86. PubMed ID: 24403233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tebentafusp for the treatment of metastatic uveal melanoma.
    Schank TE; Hassel JC
    Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment of uveal melanoma liver metastases.
    Brasiuniene B; Sokolovas V; Brasiunas V; Barakauskiene A; Strupas K
    Eur J Med Res; 2011 Feb; 16(2):71-5. PubMed ID: 21463985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
    J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of metastatic malignant uveal melanoma].
    Jäckel A; Bock M; Deichmann M; Waldmann V; Näher H
    Hautarzt; 2001 Feb; 52(2):98-103. PubMed ID: 11244899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study.
    Vanaken L; Woei-A-Jin FJSH; Van Ginderdeuren R; Deroose CM; Laenen A; Missotten G; Thal DR; Bechter O; Schöffski P; Clement P
    Acta Oncol; 2023 May; 62(5):480-487. PubMed ID: 37200223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Metastatic Uveal Melanoma: Progress and Challenges.
    Spagnolo F; Picasso V; Spano L; Tanda E; Venzano C; Queirolo P
    BioDrugs; 2016 Jun; 30(3):161-72. PubMed ID: 27000042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment.
    Masaoutis C; Kokkali S; Theocharis S
    Expert Opin Investig Drugs; 2021 May; 30(5):555-569. PubMed ID: 33650931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.